Himalaya Nutravedics IPO Day 2: Subscribed 0.22x; Retail leads at 0.35x, QIB nil
- Himalaya Nutravedics IPO subscribed 0.22x cumulatively by end of Day 2.
- Retail investors led demand at 0.35x, followed by sHNIs at 0.41x.
- QIBs and Employees remained unsubscribed throughout the period.
- Issue closes on September 24, 2026, with allotment on September 25, 2026.
*this image is generated using AI for illustrative purposes only.
Himalaya Nutravedics IPO recorded a cumulative subscription of 0.22x by the end of Day 2, led by Retail investors at 0.35x and sHNIs at 0.41x, while QIB demand remained nil.
Subscription Status
The Ayurvedic and nutraceutical manufacturer's public offering saw a marginal uptick in interest on Day 2 (23-09-2026). The total subscription stood at 0.22x, an increase from the Day 1 closing of 0.11x. This progression was primarily driven by Non-Institutional Investors (sHNI) and Retail participants, while institutional appetite remained absent.
Subscription Progression
| Day | Date | QIB | NII (bHNI) | NII (sHNI) | Retail | Total |
|---|---|---|---|---|---|---|
| Day 1 | 22-09-2026 | 0.00x | 0.21x | 0.10x | 0.16x | 0.11x |
| Day 2 | 23-09-2026 | 0.00x | 0.41x | 0.10x | 0.35x | 0.22x |
Category-wise Breakdown
Retail investors emerged as the strongest category, with subscription rising to 0.35x from 0.16x on Day 1. The sHNI segment showed significant movement, jumping to 0.41x from 0.10x on Day 1. Conversely, bHNI subscription adjusted to 0.41x in the latest snapshot context provided in the data table vs previous day's 0.21x, while QIBs and Employees continued to record zero subscriptions across both days.
Intra-day Timeline
| Time (IST) | QIB | NII (bHNI) | Retail | Total |
|---|---|---|---|---|
| 11:15 | 0.00x | 0.00x | 0.30x | 0.16x |
| 12:15 | 0.00x | 0.41x | 0.35x | 0.22x |
Offer Details
The Himalaya Nutravedics IPO is open for subscription from September 22, 2026, to September 24, 2026. The price band has been set between ₹100.00 and ₹106.00 per share. The minimum bid quantity is 2400 shares.
About the Company
Himalaya Nutravedics India Limited is a Hyderabad-based manufacturer, marketer, and distributor of Ayurvedic and Nutraceutical formulations. The company operates through a hybrid business model comprising own-brand products and third-party contract manufacturing. It runs a single WHO-GMP, ISO 9001:2015, and ISO 22000:2018 certified integrated facility in Cherlapally, Hyderabad.
The company follows a doctor-centric, offline distribution model across 17 states, supported by approximately 58 sales personnel. Strategic plans include expanding pan-India presence, diversifying the product portfolio, and exploring export markets.
Financial Highlights
Revenue from operations grew significantly from ₹1,442.56 lakhs in FY2024 to ₹4,306.75 lakhs in FY2026. Profit After Tax (PAT) rose to ₹738.97 lakhs in FY2026, reflecting a shift toward higher-margin branded business.
| Particulars | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Revenue from Operations (₹ Cr) | 14.43 | 21.00 | 43.07 |
| Total Revenue (₹ Cr) | 14.43 | 21.00 | 43.12 |
| Profit Before Tax (₹ Cr) | 0.59 | 2.25 | 7.48 |
| Total Profit (₹ Cr) | 0.43 | 2.23 | 7.39 |
| Total Assets (₹ Cr) | 6.09 | 10.82 | 24.42 |
Objects of the Issue
- Funding Working Capital Requirements: To fund working capital requirements in the ordinary course of business and accelerate strategic expansion into Direct-to-Consumer (D2C) segments.
- Investment in Branding, Digital Marketing and Sales Expansion: For branding, digital marketing, sales expansion initiatives, advertising on e-commerce marketplaces, and developing a proprietary D2C website.
- General Corporate Purposes: For general corporate purposes including strategic initiatives, strengthening marketing networks, brand building, and meeting business exigencies.
Risk Factors
- High Customer Concentration Risk: The company derives over 80% of its revenue from its top 10 customers, with no long-term contractual arrangements.
- Revenue Concentration in Ayurvedic Products: Ayurvedic products accounted for 94.57% of revenue from operations in Fiscal 2026.
- Negative Cash Flows from Operating Activities: The company experienced negative operating cash flows of ₹383.44 lakhs in Fiscal 2026 due to elevated working capital requirements.
- Expiry of Tax Benefits: The tax holiday under Section 80-IAC expires after Fiscal 2027, which could reduce Profit After Tax by approximately 28% of Profit Before Tax.
- Single Manufacturing Facility: Operations are concentrated in a single leased facility in Hyderabad, exposing the company to geographical concentration risks.
What's Next
The IPO closes on September 24, 2026. Allotment is expected on September 25, 2026, with listing scheduled for September 29, 2026.
How might the persistent zero QIB subscription influence Himalaya Nutravedics' post-listing stock volatility and institutional valuation benchmarks?
Given the expiry of the Section 80-IAC tax holiday after FY2027, what specific margin preservation strategies will management implement to offset the projected 28% impact on Profit Before Tax?
Can the company successfully diversify its revenue base away from Ayurvedic products and its top 10 customers to mitigate concentration risks while executing its D2C expansion plans?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
